Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Woodline Partners LP

Woodline Partners LP boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 142,523 shares of the company's stock after purchasing an additional 10,968 shares during the period. Woodline Partners LP's holdings in Moderna were worth $5,926,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Two Sigma Investments LP lifted its position in shares of Moderna by 5.8% during the 4th quarter. Two Sigma Investments LP now owns 664,040 shares of the company's stock worth $27,611,000 after buying an additional 36,558 shares in the last quarter. Theleme Partners LLP increased its stake in shares of Moderna by 1.0% in the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after purchasing an additional 72,028 shares in the last quarter. Tang Capital Management LLC purchased a new position in Moderna during the fourth quarter valued at approximately $12,474,000. Tema Etfs LLC purchased a new position in Moderna during the fourth quarter valued at approximately $394,000. Finally, Toronto Dominion Bank grew its stake in Moderna by 75.2% in the 4th quarter. Toronto Dominion Bank now owns 230,320 shares of the company's stock worth $9,577,000 after buying an additional 98,843 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

NASDAQ MRNA traded up $0.96 on Thursday, hitting $27.01. 4,452,309 shares of the stock were exchanged, compared to its average volume of 8,029,064. The stock has a fifty day moving average price of $26.70 and a two-hundred day moving average price of $34.14. The firm has a market capitalization of $10.45 billion, a P/E ratio of -2.90 and a beta of 1.99. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $158.82.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($3.07) earnings per share. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MRNA shares. Morgan Stanley cut their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Citigroup started coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada cut their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Finally, Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $53.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.